Novocure

About Novocure

Novocure is a pioneering oncology company dedicated to improving the lives of patients with cancer through innovative therapies. Founded in 2000, the company has developed a unique treatment modality known as Tumour Treating Fields (TTFields), which uses electric fields to disrupt cancer cell division.

Headquartered in the UK, Novocure operates globally, providing its groundbreaking therapies to patients in various countries. The company’s flagship product, Optune, is specifically designed for the treatment of glioblastoma, a highly aggressive form of brain cancer.

Novocure’s mission is to extend survival and improve the quality of life for patients battling cancer. The company invests heavily in research and development, continuously seeking to expand its portfolio of TTFields-based therapies for other types of solid tumours.

With a commitment to patient-centric care, Novocure collaborates with healthcare professionals and institutions to ensure that its therapies are accessible and effective. The company also engages in educational initiatives to raise awareness about the potential of TTFields in cancer treatment.

As a leader in the field of bioelectronic medicine, Novocure is at the forefront of transforming cancer care. The company’s vision is to create a world where cancer is no longer a life-threatening disease, but a manageable condition.

• Innovative Therapies: Focused on developing non-invasive treatments for cancer.
• Global Reach: Providing therapies to patients worldwide.
• Research-Driven: Committed to advancing cancer treatment through continuous research.

Through its dedication to innovation and patient care, Novocure is reshaping the landscape of oncology and offering hope to patients and families affected by cancer.